Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10029774 | 0.91 | TSHR (0.36) | TSHR | |
| SCHEMBL23508852 | 0.91 | TSHR (0.36) | TSHR | |
| SCHEMBL28291698 | 0.91 | TSHR (0.36) | TSHR | |
| SCHEMBL13006491 | 0.89 | ALDH1A1 (0.32) | TSHR | |
| SCHEMBL12808432 | 0.88 | TSHR (0.38) | TSHR | |
| SCHEMBL366645 | 0.87 | TSHR (0.38) | TSHR | |
| Boric Acid SCHEMBL27917377 | 0.86 | ANPEP (0.33) | TSHR | |
| SCHEMBL10522989 | 0.85 | TSHR (0.36) | TSHR | |
| SCHEMBL20967951 | 0.85 | TSHR (0.40) | TSHR | |
| SCHEMBL9912385 | 0.85 | TSHR (0.40) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019186497-A1 | DIPEPTIDE PIPERIDINE DERIVATIVES | Oncoarendi Therapeutics S.A. (PL) | 2019-10-03 | — | — | WO | disclosed |
| US-9394289-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-19 | — | — | US | disclosed |
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-25 | — | — | US | disclosed |
| US-8859602-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-7575846-B2 | Resist polymer and resist composition | MITSUBISHI RAYON CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| CN-1408739-A | (Melhy) propenyl series crosslink micro particles and its producing process | NIPPON CATALYTIC CHEM IND (JP) | 2003-04-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378457-A1 | INHIBITORS OF C-FMS KINASE | MUSK, FRK, FES | TSHR 1277/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | TSHR 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.